English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Thirty years ago the now Nobel Prize winner Harald Zur Hausen first described high-risk human papillomavirus (hrHPV) type 16 in cervical cancer specimens (Fig. 1). Since then, hrHPV infection has been established as a prerequisite for the development of cervical cancer. Cervical cancer prevention programmes in many developed countries already include primary prevention through immunisation against hrHPV types 16 and 18 before hrHPV exposure, combined with secondary prevention via cytology-based screening, often augmented by testing for hrHPV infection. The benefit of acquired knowledge and new technologies must now be extended to developing countries, where 85% of deaths attributable to cervical cancer occur.www.samj.org.zaam201

Paradigm shift needed for cervical cancer: HPV infection is the real epidemic